Achievement of sustained drug-free remission in GCA is rare; relapses and the need for GC boluses were associated with requiring long-term GC treatment.
Glooko Inc. and Hedia ApS launched an integrated software solution in the U.K. to support people with diabetes who require advanced doses of bolus insulin. The solution combines Glooko’s diabetes ...
CeQur announced today that it closed a $120 million financing round to support its wearable insulin delivery technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback